Pfizer Works With Roche To Increase Diagnostic Services For Xalkori Launch In China’s Self-Pay Market
This article was originally published in PharmAsia News
Executive Summary
Despite no reimbursement in sight, Pfizer still sees a huge potential for targeted lung cancer drug Xalkori in China. To quickly ramp up eligible patients, Pfizer is working with Roche to offer discounted diagnostic services to identify best responders.
You may also be interested in...
Xalkori And Zelboraf: The Highs And Lows Of Commercializing Targeted Cancer Drugs
Pfizer’s lung cancer drug Xalkori and Roche’s melanoma drug Zelboraf launched last year in tandem with companion diagnostics. But a slow launch trajectory compared to other recent cancer drugs points to pitfalls for marketing a drug to just a subset of patients.
Chinese-Language Podcast: 聊聊七月生物制药热门话题
Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector.
Lost In Translation? New Zoonotic Virus Naming Gets China's Largest Physician Platform In Trouble
China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.